MedPath

Comparison Between FDG-PET and MRI for the Assessment of Response to Intensive Chemotherapy in Multiple Myeloma Patients.

Not Applicable
Terminated
Conditions
Multiple Myeloma
Registration Number
NCT00200668
Lead Sponsor
Nantes University Hospital
Brief Summary

Comparison between FDG-PET and MRI for the assessment of response to intensive chemotherapy in multiple myeloma patients.

Detailed Description

First whole body FDG-PET scan and MRI before the start of the treatment. Second whole body FDG-PET scan and MRI after the end of the treatment. On a basis of patient, comparison between PET and MRI will be done tumoral site by site. Sensitivity, Specificity will be estimated for both techniques. In case of discrepancy, another imaging method or biopsy (if easy to perform) will be serve as standard of reference. Kappa coefficients and Mc Nemar test will be performed to compare the two methods. FDG = fluorodeoxyglucose FLUCIS® (Schering-CisBio® international)

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  • Patients from 18 to 65 years old.
  • De novo histologically proven multiple myeloma.
Exclusion Criteria
  • No history of another cancer or of HIV
  • No history of renal failure

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Nantes University Hospital

🇫🇷

Nantes, France

© Copyright 2025. All Rights Reserved by MedPath